{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Omeros Corporation"},"Symbol":{"label":"Symbol","value":"OMER"},"Address":{"label":"Address","value":"201 ELLIOTT AVENUE WEST, SEATTLE, Washington, 98119, United States"},"Phone":{"label":"Phone","value":"+1 206 676-5000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders."},"CompanyUrl":{"label":"Company Url","value":"https://www.omeros.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andreas Grauer","title":"Chief Medical Officer"},{"name":"George A. Gaitanaris","title":"Chief Scientific Officer & Vice President-Science"},{"name":"Gregory A. Demopulos","title":"Chairman, President & Chief Executive Officer"},{"name":"J. Steven Whitaker","title":"Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}